Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2011

Open Access 01-12-2011 | Research

In vitro characterization of cells derived from chordoma cell line U-CH1 following treatment with X-rays, heavy ions and chemotherapeutic drugs

Authors: Takamitsu A Kato, Akihisa Tsuda, Mitsuru Uesaka, Akira Fujimori, Tadashi Kamada, Hirohiko Tsujii, Ryuichi Okayasu

Published in: Radiation Oncology | Issue 1/2011

Login to get access

Abstract

Background

Chordoma, a rare cancer, is usually treated with surgery and/or radiation. However, very limited characterizations of chordoma cells are available due to a minimal availability (only two lines validated by now) and the extremely long doubling time. In order to overcome this situation, we successfully derived a cell line with a shorter doubling time from the first validated chordoma line U-CH1 and obtained invaluable cell biological data.

Method

After isolating a subpopulation of U-CH1 cells with a short doubling time (U-CH1-N), cell growth, cell cycle distribution, DNA content, chromosome number, p53 status, and cell survival were examined after exposure to X-rays, heavy ions, camptothecin, mitomycin C, cisplatin and bleocin. These data were compared with those of HeLa (cervical cancer) and U87-MG (glioblastoma) cells.

Results

The cell doubling times for HeLa, U87-MG and U-CH1-N were approximately 18 h, 24 h and 3 days respectively. Heavy ion irradiation resulted in more efficient cell killing than x-rays in all three cell lines. Relative biological effectiveness (RBE) at 10% survival for U-CH1-N was about 2.45 for 70 keV/μm carbon and 3.86 for 200 keV/μm iron ions. Of the four chemicals, bleocin showed the most marked cytotoxic effect on U-CH1-N.

Conclusion

Our data provide the first comprehensive cellular characterization using cells of chordoma origin and furnish the biological basis for successful clinical results of chordoma treatment by heavy ions.
Appendix
Available only for authorised users
Literature
1.
Azzarelli A, Quagliuolo V, Cerasoli S, Zucali R, Bignami P, Mazzaferro V, Dossena G, Gennari L: Chordoma: natural history and treatment results in 33 cases. J Surg Oncol 1988,37(3):185-191. 10.1002/jso.2930370311CrossRefPubMed
2.
Sundaresan N, Galicich JH, Chu FC, Huvos AG: Spinal chordomas. J Neurosurg 1979,50(3):312-319. 10.3171/jns.1979.50.3.0312CrossRefPubMed
3.
Catton C, O'Sullivan B, Bell R, Laperriere N, Cummings B, Fornasier V, Wunder J: Chordoma: long-term follow-up after radical photon irradiation. RadiotherOncol 1996,41(1):67-72.
4.
Cheng EY, Ozerdemoglu RA, Transfeldt EE, Thompson RC Jr: Lumbosacral chordoma. Prognostic factors and treatment. Spine (Phila Pa 1976) 1999,24(16):1639-1645. 10.1097/00007632-199908150-00004CrossRef
5.
Combs SE, Ellerbrock M, Haberer T, Habermehl D, Hoess A, Jakel O, Jensen A, Klemm S, Munter M, Naumann J, Nikoghosyan A, Oertel S, Parodi K, Rieken S, Debus J: Heidelberg Ion Therapy Center (HIT): Initial clinical experience in the first 80 patients. Acta Oncol 2010,49(7):1132-1140. 10.3109/0284186X.2010.498432CrossRefPubMed
6.
Fagundes MA, Hug EB, Liebsch NJ, Daly W, Efird J, Munzenrider JE: Radiation therapy for chordomas of the base of skull and cervical spine: patterns of failure and outcome after relapse. Int J Radiat Oncol Biol Phys 1995,33(3):579-584. 10.1016/0360-3016(95)02014-3CrossRefPubMed
7.
Henderson FC, McCool K, Seigle J, Jean W, Harter W, Gagnon GJ: Treatment of chordomas with CyberKnife: georgetown university experience and treatment recommendations. Neurosurgery 2009,64(2 Suppl):A44-A53.CrossRefPubMed
8.
Imai R, Kamada T, Tsuji H, Sugawara S, Serizawa I, Tsujii H, Tatezaki S: Effect of carbon ion radiotherapy for sacral chordoma: results of Phase I-II and Phase II clinical trials. Int J Radiat Oncol Biol Phys 2010,77(5):1470-1476. 10.1016/j.ijrobp.2009.06.048CrossRefPubMed
9.
Imai R, Kamada T, Tsuji H, Yanagi T, Baba M, Miyamoto T, Kato S, Kandatsu S, Mizoe JE, Tsujii H, Tatezaki S: Carbon ion radiotherapy for unresectable sacral chordomas. Clin Cancer Res 2004,10(17):5741-5746. 10.1158/1078-0432.CCR-04-0301CrossRefPubMed
10.
Schoenthaler R, Castro JR, Petti PL, Baken-Brown K, Phillips TL: Charged particle irradiation of sacral chordomas. Int J Radiat Oncol Biol Phys 1993,26(2):291-298. 10.1016/0360-3016(93)90209-ECrossRefPubMed
11.
Schulz-Ertner D, Nikoghosyan A, Didinger B, Karger CP, Jakel O, Wannenmacher M, Debus J: Treatment planning intercomparison for spinal chordomas using intensity-modulated photon radiation therapy (IMRT) and carbon ions. Phys Med Biol 2003,48(16):2617-2631. 10.1088/0031-9155/48/16/304CrossRefPubMed
12.
Schulz-Ertner D, Nikoghosyan A, Thilmann C, Haberer T, Jakel O, Karger C, Scholz M, Kraft G, Wannenmacher M, Debus J: Carbon ion radiotherapy for chordomas and low-grade chondrosarcomas of the skull base. Results in 67 patients. Strahlenther Onkol 2003,179(9):598-605. 10.1007/s00066-003-1120-2CrossRefPubMed
13.
Sciubba DM, Chi JH, Rhines LD, Gokaslan ZL: Chordoma of the spinal column. Neurosurg Clin N Am 2008,19(1):5-15. 10.1016/j.nec.2007.09.006CrossRefPubMed
14.
Chugh R, Dunn R, Zalupski MM, Biermann JS, Sondak VK, Mace JR, Leu KM, Chandler WF, Baker LH: Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma. JClinOncol 2005,23(15):3597-3604.CrossRef
15.
Hof H, Welzel T, Debus J: Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma. Onkologie 2006,29(12):572-574. 10.1159/000096283CrossRefPubMed
16.
Presneau N, Shalaby A, Idowu B, Gikas P, Cannon SR, Gout I, Diss T, Tirabosco R, Flanagan AM: Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway. Br J Cancer 2009,100(9):1406-1414. 10.1038/sj.bjc.6605019PubMedCentralCrossRefPubMed
17.
Rhomberg W, Bohler FK, Novak H, Dertinger S, Breitfellner G: A small prospective study of chordomas treated with radiotherapy and razoxane. Strahlen ther Onkol 2003,179(4):249-253. 10.1007/s00066-003-1052-xCrossRef
18.
Scheil S, Bruderlein S, Liehr T, Starke H, Herms J, Schulte M, Moller P: Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1. Genes Chromosomes Cancer 2001,32(3):203-211. 10.1002/gcc.1184CrossRefPubMed
19.
Kanai T, Endo M, Minohara S, Miyahara N, Koyama-ito H, Tomura H, Matsufuji N, Futami Y, Fukumura A, Hiraoka T, Furusawa Y, Ando K, Suzuki M, Soga F, Kawachi K: Biophysical characteristics of HIMAC clinical irradiation system for heavy-ion radiation therapy. Int J Radiat Oncol Biol Phys 1999,44(1):201-210. 10.1016/S0360-3016(98)00544-6CrossRefPubMed
20.
Kanai T, Furusawa Y, Fukutsu K, Itsukaichi H, Eguchi-Kasai K, Ohara H: Irradiation of mixed beam and design of spread-out Bragg peak for heavy-ion radiotherapy. Radiat Res 1997,147(1):78-85. 10.2307/3579446CrossRefPubMed
21.
Kanai T, Matsufuji N, Miyamoto T, Mizoe J, Kamada T, Tsuji H, Kato H, Baba M, Tsujii H: Examination of GyE system for HIMAC carbon therapy. Int J Radiat Oncol Biol Phys 2006,64(2):650-656. 10.1016/j.ijrobp.2005.09.043CrossRefPubMed
22.
Matsufuji N, Fukumura A, Komori M, Kanai T, Kohno T: Influence of fragment reaction of relativistic heavy charged particles on heavy-ion radiotherapy. Phys Med Biol 2003,48(11):1605-1623. 10.1088/0031-9155/48/11/309CrossRefPubMed
23.
Matsufuji N, Kanai T, Kanematsu N, Miyamoto T, Baba M, Kamada T, Kato H, Yamada S, Mizoe JE, Tsujii H: Specification of Carbon Ion Dose at the National Institute of Radiological Sciences (NIRS). J Radiat Res(Tokyo) 2007,48(Suppl A):A81-A86.CrossRef
24.
Canman CE, Chen CY, Lee MH, Kastan MB: DNA damage responses: p53 induction, cell cycle perturbations, and apoptosis. Cold Spring Harb Symp Quant Biol 1994, 59: 277-286.CrossRefPubMed
25.
26.
Canman CE, Wolff AC, Chen CY, Fornace AJ Jr, Kastan MB: The p53-dependent G1 cell cycle checkpoint pathway and ataxia-telangiectasia. Cancer Res 1994,54(19):5054-5058.PubMed
27.
Gueven N, Becherel OJ, Birrell G, Chen P, DelSal G, Carney JP, Grattan-Smith P, Lavin MF: Defective p53 response and apoptosis associated with an ataxia-telangiectasia-like phenotype. Cancer Res 2006,66(6):2907-2912. 10.1158/0008-5472.CAN-05-3428CrossRefPubMed
28.
Crawford LV, Pim DC, Gurney EG, Goodfellow P, Taylor-Papadimitriou J: Detection of a common feature in several human tumor cell lines--a 53,000-dalton protein. Proc Natl Acad Sci USA 1981,78(1):41-45. 10.1073/pnas.78.1.41PubMedCentralCrossRefPubMed
29.
Kondo S, Barna BP, Kondo Y, Tanaka Y, Casey G, Liu J, Morimura T, Kaakaji R, Peterson JW, Werbel B, Barnett GH: WAF1/CIP1 increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis. Oncogene 1996,13(6):1279-1285.PubMed
30.
Willis A, Jung EJ, Wakefield T, Chen X: Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene 2004,23(13):2330-2338. 10.1038/sj.onc.1207396CrossRefPubMed
31.
Naka T, Boltze C, Kuester D, Schulz TO, Schneider-Stock R, Kellner A, Samii A, Herold C, Ostertag H, Roessner A: Alterations of G1-S checkpoint in chordoma: the prognostic impact of p53 overexpression. Cancer 2005,104(6):1255-1263. 10.1002/cncr.21296CrossRefPubMed
32.
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006,444(7120):756-760. 10.1038/nature05236CrossRefPubMed
33.
Kruuv J, Sinclair WK: X-ray sensitivity of synchronized Chinese hamster cells irradiated during hypoxia. Radiat Res 1968,36(1):45-54. 10.2307/3572536CrossRefPubMed
34.
Park SA, Kim HS: F-18 FDG PET/CT evaluation of sacrococcygeal chordoma. Clin Nucl Med 2008,33(12):906-908. 10.1097/RLU.0b013e31818c4e88CrossRefPubMed
35.
Brurberg KG, Skogmo HK, Graff BA, Olsen DR, Rofstad EK: Fluctuations in pO2 in poorly and well-oxygenated spontaneous canine tumors before and during fractionated radiation therapy. Radiother Oncol 2005,77(2):220-226. 10.1016/j.radonc.2005.09.009CrossRefPubMed
36.
Cooper RA, Carrington BM, Loncaster JA, Todd SM, Davidson SE, Logue JP, Luthra AD, Jones AP, Stratford I, Hunter RD, West CM: Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. Radiother Oncol 2000,57(1):53-59. 10.1016/S0167-8140(00)00259-0CrossRefPubMed
37.
Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, Becker A, Adam M, Molls M, Dunst J, Terris DJ, Overgaard J: Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005,77(1):18-24. 10.1016/j.radonc.2005.06.038CrossRefPubMed
38.
Davis MA, Little JB: RBE and OER of the heavy ionizing particles released during 10beta-neutron capture therapy. Rev Latino am Microbiol Parasitol (Mex) 1968,10(2):207.
39.
Bassler N, Jakel O, Sondergaard CS, Petersen JB: Dose- and LET-painting with particle therapy. Acta Oncol 2010,49(7):1170-1176. 10.3109/0284186X.2010.510640CrossRefPubMed
40.
Tsujii H, Mizoe J, Kamada T, Baba M, Tsuji H, Kato H, Kato S, Yamada S, Yasuda S, Ohno T, Yanagi T, Imai R, Kagei K, Hara R, Hasegawa A, Nakajima M, Sugane N, Tamaki N, Takagi R, Kandatsu S, Yoshikawa K, Kishimoto R, Miyamoto T: Clinical Results of Carbon Ion Radiotherapy at NIRS. J Radiat Res(Tokyo) 2007,48(Suppl A):A1-A13.CrossRef
Metadata
Title
In vitro characterization of cells derived from chordoma cell line U-CH1 following treatment with X-rays, heavy ions and chemotherapeutic drugs
Authors
Takamitsu A Kato
Akihisa Tsuda
Mitsuru Uesaka
Akira Fujimori
Tadashi Kamada
Hirohiko Tsujii
Ryuichi Okayasu
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2011
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/1748-717X-6-116

Other articles of this Issue 1/2011

Radiation Oncology 1/2011 Go to the issue

Research

An ultrasonographic evaluation of skin thickness in breast cancer patients after postmastectomy radiation therapy

Research

Risk factors of distant brain failure for patients with newly diagnosed brain metastases treated with stereotactic radiotherapy alone

Research

Inter-observer variability in contouring the penile bulb on CT images for prostate cancer treatment planning

Short report

Curative treatment of oesophageal carcinoma: current options and future developments

Research

Spinal radiosurgery - efficacy and safety after prior conventional radiotherapy

Research

Clinical application of CT-guided 125I seed interstitial implantation for local recurrent rectal carcinoma